Consumer healthcare company HRA Pharma grew their total group revenues by 20.8% in 2019 with EBITDA growing by 30%
Consumer healthcare company HRA Pharma grew their total group revenues by 20.8% in 2019 with EBITDA growing by 30%
Today, consumer healthcare company HRA Pharma reports that total group revenues rose by 20.8% to €253.8m in 2019 (year-end December 31), from €210.1m in 2018 and €119.0m in 2017.
HRA Pharma’s revenue growth last year was driven by the strong performance of its category leading blister brand Compeed. Revenue growth was also supported by HRA Pharma’s rare disease affiliate and ellaOne, where revenues rose by 18% and 15% respectively. The successful integration of Mederma, which HRA Pharma acquired in June 2019, also supported revenue growth. Excluding Mederma organic revenue growth was 14%
Total group EBITDA grew by 30% with a margin of 29.6% when compared to 2018.
David Wright, CEO of HRA Pharma, says, “We are delighted to report our considerable revenue growth and consistently high EBITDA margin, which shows that we continue to outpace the market as a whole.”
“These figures certainly justify HRA Pharma’s strategic decision to focus on building our category leading brands and geographically expanding in key countries such as the USA and China and key regions including the Middle East and Asia.
END
For more information, please contact:
Corinna Mason / corinna@mediazoo.tv / 07713 470 683
Joseph Wade / joseph@mediazoo.tv / 07758 074 576
About HRA Pharma:
HRA Pharma are one of the fastest growing consumer healthcare companies in the world and has a strong focus on prescription to over the counter switches. Created in 1996, the objective at the creation of HRA Pharma was to provide innovative solutions to medical needs that had not been addressed previously by large pharmaceutical groups.
Now HRA Pharma are leaders within the market segments they operate in. After growing the brand with new products and markets, they are now number one in emergency contraception, scar and blister care in Europe.
HRA Pharma aim to more than double in size by 2022 by using a combination of swift switching, new products, geographic expansion and smart acquisitions. Currently, HRA Pharma has direct operational presence in 11 European countries and partnerships that have extended its products’ availability to over 90 countries worldwide.
